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The Kinin B2 receptor (B2R) is classically involved in vasodilation and inflammatory
responses. However, through the observation of hypoglycemic effects of Angiotensin-I-
Converting Enzyme (ACE) inhibitors, this protein has been related to metabolic glucose
modulation in physiological and pathophysiological contexts. Although several studies
have evaluated this matter, the different methodologies and models employed, combined
with the distinct target organs, results in a challenge to summarize and apply the
knowledge in this field. Therefore, this review aims to compile human and animal data
in order to provide a big picture about what is already known regarding B2R and glucose
metabolism, as well to suggest pending investigation issues aiming at evaluating the role
of B2R in relation to glucose metabolism in homeostatic situations and metabolic
disturbances. The data indicate that B2R signaling is involved mainly in glucose uptake
in skeletal muscle and adipose tissue, acting as a synergic player beside insulin. However,
most data indicate that B2R induces increased glucose oxidation, instead of storage, via
activation of a broad signaling cascade involving Nitric Oxide (NO) and cyclic-GMP
dependent protein kinase (PKG). Additionally, we highlight that this modulation is
impaired in metabolic disturbances such as diabetes and obesity, and we provide a
hypothetic mechanism to explain this blockade in light of literature data provided for this
review, as well as other authors.
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The Kallikrein-kinin system (KKS) consists of a group of
proteins and peptides which play an important role in several
physiological functions, such as vasodilation, inflammatory
responses, and metabolic adaptations. The precursor of this
system is Kininogen, which can be cleaved by Kallikrein to
give rise to Kinins, peptides that possess the ability to induce
physiological alterations through the kinin B2 receptor (B2R).
These peptides can be further cleaved to generate an agonist for a
second receptor, the kinin B1 receptor (B1R). While the B2R is
broadly expressed in physiological conditions, the B1R seems to be
more important in the inflammatory context (Pesquero et al., 2000;
Talbot et al., 2011; Murugesan et al., 2016; Qadri and Bader, 2018).
Moreover, kinins can be also cleaved by the Angiotensin-
Converting Enzyme (ACE), which generates inactive peptides that
can enter the degradation process (Deddish et al., 1996; Dendorfer
et al., 1999; Moreau et al., 2005).
The first studies aiming to analyze the relationship between
B2R and glucose homeostasis were driven by the evidence of
hypoglycemic effects caused by ACE inhibitors (ACEi) on
hypertensive patients (Arauz-Pacheco et al., 1990).
These results led the researchers to focus on additional
benefits of ACEi for these patients, since glycemic disturbances
are commonly found in association with hypertension (Mitchell
et al., 1990; Haffner et al., 1998; Juutilainen et al., 2005; Hoffman
et al., 2015).
In this context, kinins emerged as the main candidate to be
the active agent in this adaptation, since it was observed that
ACEi-mediated glycemic effects could not be attributed to
decreased Angiotensin II synthesis (Rosenthal et al., 1997).
The articles cited in this review explore the relationship
between kinins and glucose homeostasis through two main
strategies: analyses of ACEi-mediated effects, and direct effects
of kinins on different physiological situations.
Even though the number of publications addressing B2R-
modulated glucose metabolism is considerable, the huge
variation in the methodologies used becomes a challenge when
we intend to combine all aspects into a general picture.
Therefore, the purpose of this review is to compile informationAbbreviations: B2R, kinin B2 receptor; ACEi, Angiotensin-I-Converting Enzyme
inhibitor; KKS, kallikrein-kinin-system; B1R, kinin b1 receptor; ACE, angiotensin-I-
converting enzyme; SHR, spontaneous hypertensive rat; NO, nitric oxide; STZ,
streptozotocin; GLUT 4, glucose transporter type 4; B2KO, kinin b2 receptor
knockout mouse; HFD, high fat diet; JNK, c-jun kinase; PKG, cyclic GMP-
dependent protein kinase; MKP-5, mitogen-activated protein kinase phosphatase
5; PI3K, phophoinositide 3- kinase; eNOS, endothelial nitric oxide synthase; PKC,
protein kinase C; CaMK, calcium-calmodulin-dependent protein kinase; AMPK,
AMP-activated protein kinase; cGMP, cyclic guanosine-monophosphate; iNOS,
inducible nitric oxide synthase; IRS-beta, insulin-receptor-substrate beta subunit;
AKT, protein kinase B; G-alpha-i, GTP-binding protein alpha subunits Gi-Go;
NADPH-oxydase, Nicotinamide adenine dinucleotide phosphate oxydase; CPM,
carboxypeptidase typeM; BK, bradykinin; IRS1, insulin receptor substrate type 1; IR,
insulin receptor; KD, kallidin; Plc, phospholipase C; DABK, des-arg-9-bradykinin;
DAKD, des-arg-10-kallidin; Src, SRC family tyrosine kinases; Ras, small GTPases;
Raf, small GTPases; MEK, mitogen-activated protein-kinase kinase; ERK,
extracellular signal-regulated kinase; HOE140, B2 kinin receptor inhibitor; L-
NAME, nitric oxide synthase inhibitor.
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the area, as well as to suggest new directions for future research.METHODS
We selected articles published between 1990 and 2020 specifically
aimed at evaluating the role of B2R in glucose metabolism. For the
articles to be included in this review, they should meet the following
inclusion criteria: original communications, article data obtained in
mammal species, articles in animal models should have some
strategy to ensure that treatment effects would be exclusively
resulting from B2R signaling, and finally, the articles should be
published in English language.
The search was carried out in MEDLINE/PubMed (https://
www.ncbi.nlm.nih.gov/pubmed/) and the keywords/terms used
were: b2 kinin receptor, b2 knockout mice, bradykinin and Ace
inhibitors plus the term “glucose metabolism”. Thus, we had a
total of four search combinations: “b2 kinin receptor AND
glucose metabolism”; “b2 knockout mice AND glucose
metabolism”; “bradykinin AND glucose metabolism” and “Ace
inhibitors AND glucose metabolism”.
Upon abstract analysis by two independent investigators,
duplicated articles were excluded, as well as those which did
not fulfill our criteria. Ultimately, 41 articles were selected. More
details about the search process can be found in Figure 1 and
Supplementary Materials. We also provide the summarized
findings of included articles in Table 1.
Due to a large variation in the aim of the studies, we divided
the results into sections for best understanding.
Systemic Researches
Regarding systemic adaptations, the effects of B2R signaling on
glycemic status seem to be related to sympathetic drive in
anesthetized rats. The constant infusion of bradykinin (BK) caused
an increase in glucose blood content, which was abolished when
beta-blockers were administered concomitantly. On the other hand,
in adrenalectomized rats, B2R induced increased insulin secretion, as
well as reduced blood glucose levels, showing that the sympathetic
drive can change the B2 kinin receptor effects (Damas et al., 2001).
When kininogen (kinins precursor)-deficient Brown-Norway
Katholiek rats were employed to study the role of kinins in
glucose homeostasis, it was shown that these animals had glucose
intolerance, and delayed insulin response compared with the
control rats. When the authors made a screening to elucidate the
reasons for these results, they found that the absence of B2R
signaling was the source of the disturbances observed (Damas
et al., 1999).
Also, SHR rats (genetically hypertensive rats) were sensitive
to B2R signaling concerning glucose uptake. When these animals
were treated with Enalapril for 3 weeks, the glucose uptake was
improved, in addition to benefits related to arterial pressure.
Interestingly, only the adaptations in glucose metabolism
were B2R-dependent (Tomiyama et al., 1994). Another genetic
model in which the B2R signaling showed positive effects was an
obesity model in rats (obese Zucker rats).August 2020 | Volume 11 | Article 1162
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signaling improved the glucose sensitivity measured by
hyperinsulinemic-euglycemic clamp.The positive effects
induced by B2R activation were mediated by nitric oxide (NO)
production (Arbin et al., 2001; Wang et al., 2003).
In the same model, although glucose uptake was not
improved by ACEi plus B2R signaling, treatment with kinin B2
receptor antagonist caused weight gain in these animals,
suggesting an important effect mediated by this pathway in
keeping a stable energetic balance (Schaffer et al., 2004).
Dietetic interventions were also used to evaluate the role of
B2R in glucose metabolism.
After a 4-week fructose intervention in rats, 2 weeks of
treatment with the ACEi Delapril reversed hyperglycemia and
insulin resistance, but this was independent of B2R signaling
(Shimamoto et al., 1996).
Corroborating these results, in an 8-week fructose intervention,
similar results were found, since ACEi treatment decreased the body
weight of the rats, without interference of B2R signaling. However,
when the authors blocked this receptor, they observed a worsened
insulin resistance in the fructose-treated animals, suggesting
independent and likely synergistic actions of ACEi and B2R
signaling (Chen et al., 1996).
In a type 1 diabetes model (induced by STZ injection) mice
treated with B2R agonists or antagonists for 13 days showed no
effect related to glycemic homeostasis mediated by this signaling
pathway (Zuccollo et al., 1996; Zuccollo et al., 1999; Tan
et al., 2007).Frontiers in Pharmacology | www.frontiersin.org 3In rats, the inhibition of B2R signaling caused improvements in
metabolic outcomes: glycaemia and triglycerides decreased in
animals treated with B2R inhibitors, as well as NO synthesis
inhibitors (González et al., 1997), suggesting that, in this context,
B2R/NO signaling negatively modulates the metabolic adaptations,
maybe due to inflammatory environment.
On the other hand, in type I diabetic rats, an intervention
consisting of human Kallikrein I gene delivery was able to improve
blood glucose, decrease epididymal fat pad weight and increase
gastrocnemius weight. Although B2R did not influence glycemic
improvements, this signaling was responsible for the reductions in
epididymal fat content and skeletal muscle mass, contributing with
the better metabolic profile (Montanari et al., 2005).
Using ACE inhibitors initially in dogs, Uehara et al. (1994)
showed that the increased insulin sensitivity caused by Captopril
was dependent on B2R signaling, and this result was repeated in
diabetic animals, suggesting that maybe some intra-species differences
can be observed in relation to outcomes in diabetic state. Also, the
authors were able to repeat these observations in non-diabetic and
diabetic human subjects, since ACEi injection improved insulin
sensitivity in both patient groups, and this adaptation was observed
along with an increase in plasma BK content.
Skeletal Muscle
The skeletal muscle has been shown as a tissue with a huge role in
several physiologic responses, some of them related with glucose
metabolism regulation. However, in this section our focus will be
the glucose uptake. It is already well known that there are “brain-
periphery” circuits which control glucose homeostasis through
feedback mechanisms between the brain and liver, adipose tissue,
pancreas, and skeletal muscle (Balthasar et al., 2004; Dhillon et al.,
2006; Leinninger et al., 2009; Kuliczkowska-Plaksej et al., 2012).
It seems that B2R signaling may take part in this process,
since it has been shown in mice that B2R signaling in skeletal
muscle was related to the central action of leptin, being part of
responses aimed to promote glucose uptake. Leptin induced
bradykinin release in the bloodstream, which activates B2R
signaling in epitrochlearis muscle. This activation increased
NO production and induced skeletal muscle glucose uptake in
an insulin-independent pathway, suggesting additive effect of
B2R and insulin signaling (Schiuchi et al., 2001).
Also, in healthy rats, B2R signaling was effective in
modulating glucose uptake in epitrochlearis muscle, without
affecting muscle contraction (Dumke et al., 2002). In a rat
genetic model of obesity, a 14-day treatment with ACEi was
able to improve glucose uptake in epitrochlearis, and the effects
induced by B2R/NO signaling were observed only in the
presence of insulin, suggesting a cooperative, but not
independent, role for this pathway (Henriksen and Jacob, 1995;
Henriksen et al., 1996; Henriksen et al., 1999).
In a genetic model of type 2 diabetes, an improvement in
skeletal muscle glucose uptake was also observed after treatment
with ACEi for 8 weeks in mice. These effects in hindlimb muscles
were, again, mediated by B2R/NO independent of insulin and, as
a mechanism for increased glucose uptake, the authors showed
increased GLUT4 translocation towards cell membrane
(Schiuchi et al., 2002).FIGURE 1 | Flow chart showing search process.August 2020 | Volume 11 | Article 1162
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Article Sample Tissue Methods Findings
Uehara et al., 1994 Dogs and humans Sistemic analisys Chronic (in vitro) ACE inhibitor
and HOE 140 treatments
ACEi improved insulin sensitivity and this result seemed
to be related to BK.
Tomiyama et al., 1994 Rats - SHR Sistemic analisys Chronic (in vivo) Enalapril,
losartan and HOE 140
treatments
The improvement in insulin sensibility by ACEi was kinin
dependent (B2R).
Yang and Hsu, 1995 Rats Pancreas (perfused) Animals treated with BK (1uM)
and HOE 140 (0.1uM) - acute
treatment
BK increased insulin release and may play a
physiologic role in this regulation.
Henriksen and Jacob,
1995
Rats - Zucker Skeletal muscle Captopril and HOE 140 - acute
and chronic treatments in vivo
Captopril ameliorated glucose uptake in skeletal
muscle through BK.
Henriksen et al., 1996 Rats - Zucker Epitrochlearis muscle ACEi (acute and chronic in vivo
administration) and HOE 140.
ACEi increased insulin sensitivity. The acute effect was
abolished by pretreatment with HOE 140.
Chen et al., 1996 Rats - Wistar Sistemic analisys HOE 140, alacepril and TCV-116
(chronic in vivo treatments)
HOE 140 did not improve glucose tolerance
suggesting that the effects of ACE inhibitors were not
due to kinins.
Zuccollo et al., 1996 Mice - Male C57BL/
Ks mdb
Sistemic analisys STZ injection (40mg/kg) for 5
days and consecutive treatment
with B1R or B2R antagonist.
HOE 140 did not show effects. B1R antagonist
normalized glycemia and diuresis, protein, nitrite and
kallikrein excretion.
Saito et al., 1996 Hamster Cells BK and HOE 140 acute in vivo
treatments
BK increased calcium and induced the insulin release.
HOE 140 prevented the effect.
Nuutila et al., 1996 Humans Sistemic analisys BK and insulin acute in vivo
treatments
BK increases skeletal muscle blood flow but not
muscle glucose uptake in vivo.
Shimamoto et al.,
1996
Rats Sistemic analisys Delapril (ACEi) and HOE 140 -
chronic in vivo treatments
The hypoglycemic effects of ACEi were not related to
BK in this model.
González et al., 1997 Rats (streptozotocin-
diabetics rats)
Liver and uterus Chronic in vivo administration of
HOE-140 and L-NAME
Suggests that N.O production induced by B2 kinin
receptor would be responsible for some of STZ
damage in these organs.
Yang et al., 1997 Rats Pancreas BK - acute in vivo treatment BK increased insulin concentration and had a similar
transitory effect on glucagon.
Kishi et al., 1998 Rat, Mouse and
Hamster cell lines
L6: rat myotube; 3T3-L1
mouse embryo adipocytes,
CHO (hamster ovary) cells
expressing c-myc.
BK - acute treatment BK increased GLUT 4 translocation and the rate of
glucose uptake in a dose dependent way.
Laine et al., 1998 Humans (control and
obese group)
Sistemic analisys BK and insulin - acute in vivo
treatments
Glucose uptake via insulin was lower in obese





Cells - Adipocytes Enalapril, insulin and HOE 140 -
chronic in vivo treatments
HOE 140 inhibited the glucose uptake induced by
enalapril.
Damas et al., 1999 Rats Sistemic analisys Captopril and HOE 140 - in vivo
acute treatments
Animals knockout to kininogen showed impaired
functions in relation to glucose metabolism as well as
normal rats treated with HOE 140.
Henriksen et al., 1999 Rats-Zucker Epitrochlearis muscle Acei, Bk, HOE 140 and L-NAME,
insulin
Acei and/or Bk increased insulin-induced glucose
uptake, HOE104 and L-NAME abolished the effects.
Zuccollo et al., 1999 Mice - Male C57BL/
Ks mdb
Sistemic analisys STZ injection (40mg/kg) for 5
days with or without HOE140 or
ACEi
HOE140 and ACEi did not have effect in glycemia.
Kudoh and Matsuki,
2000
Rats Cell - L6 (skeletal muscle/
myoblast)
Bk, HOE 140 and enalapril -
acute in vitro treatments
ACEi induced glucose uptake via B2 kinin receptor
pathway.
Taguchi et al., 2000 Humans and rats Skeletal muscle Exercise and HOE 140 - acute in
vivo treatments
Glucose influx and GLUT4 translocation were up
regulated after exercise. These effects were abolished
after HOE 140 treatment.
Frossard et al., 2000 Humans Skeletal muscle Enalaprilat, Losartan and BK -
acute in vivo treatments
The effect in arterial interstitial gradient for glucose was
related to BK.
Damas et al., 2001 Rats Sistemic analisys BK, HOE 140 and L-NAME -
acute in vivo treatments
BK increased glucose; HOE 140 and L-NAME
abolished this effect. In specific conditions, BK also
increased insulin levels.
Shiuchi et al., 2001 Mice - FVB/N Skeletal muscle and
adipose tissue
BK, HOE 140, Leptin and L-
NAME - acute in vivo treatments
The glucose uptake induced by leptin was inhibited in
skeletal muscle by HOE 140 and L-NAME
Duka et al., 2001 Mice (WT and
B2KO)
Sistemic analisys Captopril chronic treatment - in
vivo
B2KO animals showed higher basal insulin as well as
lower sensibility to this hormone.
Arbin et al., 2001 Rats - Zucker Sistemic analisys ACE inhibitor, NEP, HOE 140
and L-NAME treatments
ACEi improved insulin mediated glucose disposal
(IMGD). ACE/NEPi improved IMGD more effectively.
HOE 140 and L-NAME inhibited the insulin sensitivity
index induced by ACE/NEPi
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insights on the role of these receptors in glucose homeostasis. The
B2KO mice had increased basal glycaemia and decreased basal
insulin content, suggesting that the absence of B2R causes
disturbances in insulin secretion. Furthermore, these animals had
impaired insulin-induced glucose uptake in soleus, with no changes
in insulin-mediated Akt phosphorylation (Schweitzer et al., 2011).
Since it has also been shown that an insulin injection was able
to increase B2R expression in skeletal muscle of wild-type mice
(Duka et al., 2001), there is the hypothesis that kinin B2 receptor
exerts an adjuvant role in insulin-induced glucose uptake.
When we look to dietetic approaches, the results are not so
homogeneous. While in rats submitted to a diet with an excessive
sucrose content ACEi could prevent insulin resistance through
B2R signaling and improvement of glycogen storage in soleus
(Cahová et al., 2003), in an HFD model, B2KO mice were
refractory to weight gain when compared with wild-type mice,Frontiers in Pharmacology | www.frontiersin.org 5and had better insulin sensitivity and increased glycogen
synthesis in the soleus. However, it is interesting to mention
that these mice had glucose intolerance (again likely due to
decreased insulin secretion) (Reis et al., 2015).
In healthy humans, acute treatment with ACEi was able to
increase vastus medialis glucose uptake during a hyperinsulinemic/
euglycemic clamp, mediated by B2R activation, corroborating the
data from animal models (Frossard et al., 2000).
Similar to what happened in animals, these data in healthy
humans predicted a positive effect of this pathway in humans with
metabolic diseases. In obese humans, a forearm BK injection
resulted in increased forearm glucose uptake, mediated by
increased NO production, corroborating the participation of the
B2R/NO pathway in skeletal muscle glucose uptake (Pretorius and
Brown, 2010). However, these data contrasted with previous studies
in healthy and obese humans, where the concomitant
administration of BK and insulin had opposite effects. AlthoughTABLE 1 | Continued
Article Sample Tissue Methods Findings
Dumke et al., 2002 Rats Skeletal muscle HOE 140 and insulin - acute in
vitro treatments
HOE 140 did not change the glucose uptake induced
by insulin.
Schiuchi et al., 2002 Mice (WT and KK-
Ay/Ta diabetic mice)




Acei, L-NAME, HOE 140-14
days in vivo treatment. Insulin
acute treatment
Acei improved insulin resistance, which was blocked
by HOE140 and L-NAME treatment. The effects were
due increased skeletal muscle glucose uptake via
GLUT4 translocation after insulin treatment
Cahová et al., 2003 Rats (HHTg and
control Wistar rats)
Sistemic analisys Captopril (chronic) and HOE 140
(acute) - in vivo treatments
Captopril and HOE 140 showed effects only in control
rats.
Wang et al., 2003 Rats - Zucker Sistemic analisys Omaprilat, ramipril, losartan and
HOE 140 - in vivo chronic
treatments
Higher glucose uptake and lower glucose production
dependent of BK.
Schaffer et al., 2004 Rats-Zucker Sistemic analisys Vasopeptidase inhibitor,icatibant
(B2R inhibitor)
There were no effects in glycemic status
Montanari et al., 2005 Rats Sistemic analisys STZ, Kallikrein gene delivery and
HOE 140
Kallikrein gene delivery improved fat pad and skeletal
muscle weight, effects abolished by HOE 140
Beard et al., 2006 Rats Cells - Adipocytes BK and HOE 140 - acute in vitro
treatments
BK enhanced insulin sensitivity in adipocytes via NO
pathway. Insulin increased glucose uptake through
IRS-1 phosphorilation.
Tan et al., 2007 Mice (WT and
B2KO)







Sistemic analisys BK e L-NAME - in vivo acute
treatments
BK increased glucose uptake and the
L-NAME treatment reversed this phenotype
Schweitzer et al., 2011 Mice - WT and
B2KO C57BL/6
Skeletal muscle Acute exercise B2R was not essential for glucose uptake after
exercise





BK - acute in vitro treatment The absence of B2R and the obesity model worsened
the animal phenotype. BK had a protective effect in
liver.
Iozzo et al., 2012 Humans - control
and obese group
Adipose tissue BK and insulin - acute in vivo
treatments
BK increased glucose uptake via insulin in control
group
Simões et al., 2013 Humans - control
and type 2 diabetes
Sistemic analisys Exercise - 3 sessions of different
kinds of moderate intensity
aerobic exercise
BK was up-regulated in control group and Des-Arg9-
BK up-regulated in diabetic group.




High fat diet and exercise -
chronic in vivo treatments
B2RKO mice had higher muscle glucose uptake,as
well as increased glygogen synthesis in insulin
stimulated condition
Asano et al., 2017 Humans - control
and type 2 diabetes
Sistemic analisys Acute aerobic exercise on a
cycle ergometer in different
intensities
BK was increased 45min after exercise. However, no
relation with the decrease of glucose and insulin was
found
Frigolet et al., 2017 Rats Cells - Adipocytes BK and insulin - acute in vitro
treatments
BK increased insulin effects by boosting signaling
pathway and inhibiting negative feedbackAugust 2020 | Volume 11 | Article 1162
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decreased in both obese subjects and healthy controls (Nuutila et al.,
1996; Laine et al., 1998).
Besides entire organism models, in vitro assays on isolated
tissues are also useful to explore the mechanisms behind the
phenotypic alterations observed in a controlled environment.
Regarding B2R signaling in L6, a skeletal muscle lineage, ACEi
treatment increased glucose uptake via GLUT4 translocation
independent of insulin (Schiuchi et al., 2002).
On the other hand, (Kudoh and Matsuki, 2000) observed B2R
effects only in presence of insulin and these were dependent on
calcium increases and activation of phospholipase C, instead of
the canonical insulin pathway (Kudoh andMatsuki, 2000). These
data open new avenues for research on the interaction between
insulin and G-coupled receptors in this tissue.
Adipose Tissue
In addition to skeletal muscle, adipose tissue is also an important
focus of kinin receptor and glucose homeostasis studies, since
this tissue also has a remarkable capacity for glucose storage and
participates in the body glucose control.
SHR rats have impaired glucose uptake and decreased
lipogenesis rate. The treatment with ACEi increased glucose
uptake mediated by insulin in adipose tissue and consequently
improved the glucose sensitivity. Interestingly, the treatment did
not change the lipogenesis induced by insulin (Caldiz and de
Cingolani, 1999) suggesting that B2R signaling can induce
glucose oxidation in adipose tissue.
In rats which developed adipose tissue insulin resistance after
being submitted to a sucrose-rich diet, treatment with ACEi
during the diet protocol was able to protect rats from
impairments on glucose uptake. Lipid storage rate was
decreased by B2R signaling only in the presence of insulin
(Cahová et al., 2003).
Further information on the glucose uptake mechanisms
triggered by B2R pathway in adipose tissue can be obtained from
in vitro approaches. The key adaptation mediated by B2R signaling
was the translocation of GLUT4 to the membrane, which was
completely independent of insulin in the NIH3T3cell line.
Furthermore, in these cells, B2R signaling was able to decrease
lipogenesis in the presence of insulin, but increased it when
administered alone (Kishi et al., 1998). In healthy rat adipocytes,
however, B2R signaling improved glucose uptake only in the
presence of insulin.
The B2R/NO pathway mediated these responses by triggering
GLUT4 translocation to the membrane through the inhibition of
the negative feedback by insulin triggered by the JNK pathway
(Beard et al., 2006). The mechanism involves PKG activation by
B2R signaling, which inhibits JNK/ERK pathways through
modulation of MKP-5, a Map-kinase dephosphatase protein
(Frigolet et al., 2017).
In humans, the ability of B2R signaling to increase adipose tissue
glucose uptake was observed only in healthy subjects submitted to a
BK injection, but not in obese subjects. However, the vasodilation
was seen in both groups (Iozzo et al., 2012).Frontiers in Pharmacology | www.frontiersin.org 6Pancreas
The pancreas is an important source of kallikrein and, in addition, it
is a central organ in glucose homeostasis through insulin and
glucagon secretion. Accordingly, Yang and Hsu (1995) decided to
investigate alterations in B2R-modulated insulin secretion. These
authors observed an increase in insulin secretion mediated by B2R
activation alone, as well as an amplification of glucose stimulated
secretion. Since the authors used the whole pancreas in the
experiments, it was not possible to distinguish between vascular
effects and direct effects on pancreatic beta cells.
In vitro studies suggested that the acute effects on the insulin
response by B2R pathway are due to calcium modulation.
Bradykinin stimulated insulin secretion in basal conditions in a
hamster beta cell line via increased reticular calcium release
(Saito et al., 1996). Furthermore, in the RINm5F line, B2R
signaling modulated cellular calcium efflux via opening of
channels in addition to modulating the endoplasmic reticulum
flux. The effects were mediated by phospholipase C and
consequent IP3 intracellular increase (Yang et al., 1997).
Liver
The effects of B2R signaling on liver glucose homeostasis
modulation were evaluated only in disease models. In leptin-
deficient mice (ob/ob mice), the additional knockout of B2R
(generating ob/ob/B2KO mice) led to impaired glycaemia
compared with ob/ob mice. While a decrease in glycaemia
could be seen in control animals, ob/ob/B2KO mice were not
able to reproduce this phenotype due to the increased gene
expression of key hepatic gluconeogenesis enzymes, which leads
to a sustained hyperglycemia (Barros et al., 2012).
In rats with type 1diabetes, the B2R/NO pathway seems to
have an important role, but promoting negative effects. The
inhibition of this pathway improved metabolic parameters, such
as triglycerides content in the liver and insulin sensitivity.
Although hepatic glucose oxidation was not affected, these data
suggest that in this model B2R signaling has an inflammatory
role (González et al., 1997).
Exercise
Physical exercise is an interesting model to evaluate stress
responses in organism in several contexts. Also, physical
exercise has been presented as an important adjuvant in the
therapy of diseases such as obesity and diabetes (Gillen et al.,
2012; Bohn et al., 2015; Pedersen and Saltin, 2015; Freitas et al.,
2018; Gorostegi-Anduaga et al., 2018). Starting from the
assumption that B2R is able to modulate glucose uptake under
resting conditions, some authors have also evaluated the action
of this receptor during physical exercise, which is a classical way
to stimulate glucose oxidation. This could be of great importance
in normal subjects, but even more in those that have some
glucose disturbances such as diabetes and obesity.
After a 60 min treadmill session of moderate intensity, B2KO
mice showed no differences in relation to controls. In both
groups, similar patterns of glucose uptake and insulin secretion
were observed (Schweitzer et al., 2011).August 2020 | Volume 11 | Article 1162
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where B2KO mice showed improved exercise performance, as
measured in both a progressive treadmill exercise and a swimming test.
The better adaptations of these animals in relation to controls
were related to a “shift” in skeletal muscle fibers from Type IIa to
Type I. These results suggest that B2R receptor can be an inducer
of glycolitic metabolism, which is not beneficial during
endurance physical exercise practice.
On the other hand, in rats with different “glycemic status”,
B2R seemed to have a role in glycemic responses after a 60 min
swimming protocol. Healthy animals, as well as diabetic animals
with controlled glycaemia, had an increase in serum BK content
along with decreased serum glycaemia.
The uncontrolled glycaemia group had a different phenotype: no
increase in BK concentration after swimming protocol and
increased glycaemia (Taguchi et al., 2000). These results suggest
that the previous glycemic status is important to BK release, and
B2R signaling. The mechanism underlying these results was
identified as increased GLUT4 translocation in hindlimb skeletal
muscles of these rats, mediated by increased phosphorylation of
PI3K in response to insulin injection.
These results were corroborated in humans by the observation of
increased BK in both healthy control and controlled type 2 diabetes
patients, after a 20 min cycloergometer session, in opposite to
patients with poor glycemic control, who could not react with the
same adaptation (Taguchi et al., 2000).
Also, in a moderate intensity aerobic training, it was found
that diabetic individuals have impaired kallikrein, BK, and NO
release compared with healthy subjects, supporting a relationship
between glycemic disturbances and poor availability of these key
compounds for the promotion of benefits related to insulin
sensitivity (Simões et al., 2013).
The intensity of training modulated glucose uptake response
in different ways. In both diabetic patient groups, increased BK
was observed only after a session at 80% of maximum capacity,
while at 120% there was no increase in the BK content. Since
glycaemia was decreased after both sessions, glycaemia was not
correlated with bradykinin responses (Asano et al., 2017).DISCUSSION
When we analyzed studies involving B2R signaling and
metabolism, we identified a pattern of response related to
glucose uptake in both adipose tissue and skeletal muscle. In
both cases, it is well established that B2R signaling improves
glucose entering into cells. This effect seems to be an
amplification pathway for insulin-induced glucose uptake
(Henriksen and Jacob, 1995; Kishi et al., 1998; Caldiz and de
Cingolani, 1999; Henriksen et al., 1999; Schiuchi et al., 2001;
Schiuchi et al., 2002; Cahová et al., 2003; Beard et al., 2006;
Frigolet et al., 2017), which is a pathway that starts with IRS-1
phosphorylation after insulin binding to its receptor IR.
Thereafter, there is phosphorylation of PI3K and Akt, leading
to GLUT4 translocation (Cheatam et al., 1994; Sano et al., 2003).
This mechanism can be seen in Figure 2A.Frontiers in Pharmacology | www.frontiersin.org 7However, there is still no answer for an important question about
the synergic effect between insulin and B2R: after glucose uptake, is
the glucose delivered to cell storage in the presence of B2R activation
similarly to what happens when only insulin is on charge? The
results of our review, along with some previous knowledge about
signaling pathways induced by the B2R allow us to raise a hypothesis.
The vast majority of articles selected for this review show that
B2R signaling is linked to eNOS activation and NO production.
These data led us to conclude that B2R modulation of glucose
uptake is dependent on calcium influx, which activates eNOS via
Plc, PKC and CaMK dependent phosphorylation (Cruzblanca et al.,
1998; Kudoh and Matsuki, 2000; Kim et al., 2006; Lee et al., 2015;
Kim et al., 2016). Therefore, NO through S-nitrosylation of AMPK,
increases glucose uptake by stimulating GLUT4 translocation to the
membrane (Fryer et al., 2000; Lira et al., 2007) (Figure 2B).
Through AMPK activation, NO would also be able to direct
glucose towards a different direction compared with the classical
actions of insulin. Indeed, at physiological concentrations, NO is
described as a factor that increases glycolysis and decreases insulin-
induced glycogen storage in skeletal muscle, in addition to being
able to decrease insulin-mediated lipogenesis (Young et al., 1997).
Additionally, there are reports in the literature describing that
the overexpression of eNOS is able to protect mice from diet-
induced obesity, mainly through mechanisms linked to increased
metabolism in adipocytes, blunting the hypertrophy of these cells
(Sansbury et al., 2012).
Furthermore, NO (from eNOS) acts through increases in
cGMP content, resulting in the activation of PKG, which can
directly activate oxidation pathways in adipose tissue through
positive modulation of Hormone Sensitive Lipase and Perilipin
(Young and Leighton, 1998).
Accordingly, Frigolet et al. (2017) showed an improved
glucose uptake mediated by the B2R/NO pathway through the
activation of PKG in adipose tissue.
Indeed, several results in this review corroborate a shift of glucose
fate induced by B2R signaling, after synergic action with insulin in
order to induce glucose uptake. This signaling pathway is able to
improve body weight or maintain it stable (Schaffer et al., 2004;
Montanari et al., 2005), and decrease the lipid storage induced by
insulin (Kishi et al., 1998; Caldiz and de Cingolani, 1999; Cahová et al.,
2003), strongly suggesting that B2R/NO pathway is an important
modulator of glucose oxidation in insulin sensitive tissues. Based on
these previous studies, we suggest that B2R/NO signaling can increase
substrate oxidation along with insulin, maybe also in an independent
way. These mechanisms are summarized in (Figure 2B).
Concerning B2R signaling and glucose metabolism, it is also
worth mentioning that a disturbed metabolic environment (obesity/
insulin resistance and/or diabetes) leads to a blockage of the B2R/
NO pathway with respect to glucose uptake (Zuccollo et al., 1996;
González et al., 1997; Zuccollo et al., 1999; Tan et al., 2007).
It is interesting to mention that these alterations are observed in
human patients with type 2 diabetes, similarly to what happens in
animal models of type 1 diabetes, which strengthens our observations
that glycemic disturbances are able to blunt B2R signaling in basal
situations, as well as endogenous BK response to physical exercise
(Taguchi et al., 2000; Simões et al., 2013).August 2020 | Volume 11 | Article 1162
Gregnani et al. B2R Signaling Increases Glucose UptakeWe hypothesized that low grade inflammatory processes, which
are common in these pathologies may be involved in these effects.
They are mediated by an increased fat content in adipose tissue and
liver, which leads to the activation of immune cells. In addition to
inflammation at local level, these tissues become a source of cytokines,
which are secreted and spread the inflammatory stimulus to other
tissues (Cox et al., 2015; Lopez et al., 2016; Borges et al., 2018).Frontiers in Pharmacology | www.frontiersin.org 8Among the players that induce and amplify these processes,
we can also find NO, which we have mentioned earlier in this text
as a protector factor in physiological situations (Yang et al., 2015;
Ghasemi and Jeddi, 2017; Liu et al., 2019).
However, if we compare the mechanism of synthesis of this
compound in pathological and physiological situations, we can see
an important difference. While in homeostatic situations the mainA B
C
FIGURE 2 | Hypothetic scheme. (A) Insulin signaling. Insulin-mediated glucose uptake in adipose tissue and skeletal muscle, which is triggered by IRS-1
phosphorylation, followed by activation of PI3k and AKT, leading to GLUT-4 translocation to membrane. (B) Kinin signaling via B2R. Signaling starts with Plc
activation, followed by calcium release from intracellular storage, CAMK activation, eNOS phosphorylation and NO synthesis, leading to AMPK and PKG activation,
and subsequently to increased GLUT4 translocation. (C) Kallikrein-Kinin System in glucose uptake. B1R is up-regulated in metabolic disturbances, as well as CPM
enzyme, converting B2R agonists (BK or KD) into B1R agonists (DABK or DAKD). B1R pathway starts with the activation of G-alpha-i and beta-gamma subunit,
leading to the activation of the following kinases: Src, Ras, Raf, MEK, and ERK.ERK activate iNOS leading to exacerbated NO production. Increased NO impairs
glucose uptake, blocking eNOS and AKT activity.August 2020 | Volume 11 | Article 1162
Gregnani et al. B2R Signaling Increases Glucose Uptakepathway of NO production is through eNOS, in pathological
situations it is produced by iNOS. This enzyme has a mechanism
of activation which is independent of calcium signaling, as well as an
increased capacity NO synthesis and long lasting activation (Stuehr
et al., 1991; Yui et al., 1991). This results in exacerbated NO
production, which can cause systemic insulin resistance as a result
of impaired glucose uptake in skeletal muscle and adipose tissue.
The mechanism involves S-nitrosylation of IRS-beta and AKT,
which interferes with glucose uptake, leading to a decrease in
muscle glycogen content (Carvalho-Filho et al., 2005; Carvalho-
Filho et al., 2006; Pauli et al., 2008; Carvalho-Filho et al., 2009) and
inhibits anti-lipolytic action of insulin in adipose tissue (Ovadia
et al., 2011). Besides that, the excessive NO production via iNOS
inhibits eNOS activity, thereby blocking the main B2R effector
(Santhanam et al., 2007; Kim et al., 2009).
Furthermore, our suggested mechanism involves a second
duality in addition to NO different role depending on the context
and its availability in intracellular compartment. We hypothesized
that the source of these disturbances is also part of KKS: B1R
activation. As previously mentioned, this receptor has a small
expression in homeostatic situations and is upregulated in
pathologic situations, including metabolic diseases. This increased
expression has functional implications, such as loss of insulin
sensitivity and increased production of reactive oxygen species
(Dias et al., 2010). The signaling pathway induced by B1R
activation implies activation of G-alpha-i protein (Brovkovych
et al., 2011), leading to increased activity of iNOS enzyme (Dias
and Couture, 2012) in addition to increased NADPH-oxidase
activity (Dias et al., 2010; Haddad and Couture, 2016). Besides
that, the role of type I Kininases (carboxypeptidases M and N) in
directly improving the function of B1R signaling pathway, as well as
amplifying those effects through B1R expression up-regulation, is
well described in the literature (Zhang et al., 2011; Zhang et al.,
2013). Indeed, CPM cellular expression is also up-regulated in
insulin resistance and the inhibition of its activity through the
experimental drug Mergetpa has positive effects similar to those
observed when B1R was blocked (Haddad and Couture, 2017).
Additionally, another experimental protocol with the same drug
corroborates our hypothesis, since the authors showed increased
vascular reactivity mediated by BK after the inhibition of type I
Kininases (Salgado et al., 1986). Based on these evidences, we
hypothesized that the negative or inconclusive results after BK
administration in human/animal interventions with obese or
diabetic subjects can be caused by a “deviation” of BK to generate
B1R agonists through type I Kininases. Therefore, the combination
of increased BK availability and increased expression/activity of type
I Kininases and B1R would lead to the pathologic frame illustrated
in Figure 2C, instead of potentiation of glucose uptake seen in
situations of physiological homeostasis, as described in Figure 2B.CONCLUSION
According to the data compiled in this review, B2R/eNOS/NO
signaling seems to be an amplifying pathway to improve glucoseFrontiers in Pharmacology | www.frontiersin.org 9uptake mediated by insulin. Furthermore, this pathway seems to
promote substrate oxidation, helping to maintain glycemic
control and body weight.
On the other hand, in metabolic diseases, there seems to be
some competition with another pathway involving KKS: B1R/
iNOS/NO. Therefore, strategies that can prevent the activation of
the B1R/NO pathway and preserve B2R/NO would be a good
approach to manage metabolic diseases such as diabetes
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